4Russell-Jones D. Molecular, pharmacological and clinical aspects of lira- glutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol, 2009,297 : 137-140.
5Rossi MC, Nicolucci A. Liraglutide in type 2 diabetes:from pharmaco- logical development to clinical practice. Acta Biomed ,2009,80:93-101.
2Drucker DJ,Nauck MA. The incretin system:glucagonlike peptide-1 re- ceptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet,2006,368 : 1696-1705.
3Salehi M, Aulinger BA, D'Alessio DA. Targeting 13-cell mass in type 2 diabetes:promise and limetations of new drugs based on incretins. En- doer Rev ,2008,29:367-379.
4Mannucci E,Tesi F,Bardini G,et al. Effects of mefformin on glucagon- like peptide-1 levels in obese patients with and without Type 2 diabe- tes. Diabetes Nutr Metab,2004,17:336-342.
5Yasuda N, Inoue T, Nagakura T, et al. Enhanced secretion of glucagon- like peptide 1 by biguanide compounds. Bioehem Biophys Res Com- mun ,2002,298:779-784.
6Knop FK. Reduced incretin effect in type 2 diabetes:cause or conse- quence of the diabetic state? Diabetes,2007,56:1951-1959.
7Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl pepti- dase-IV inhibitor vildagliptin on incretin hormones. Islet function, and postprandial glyeemia in subjects with impaired glucose tolerance. Dia- betes care ,2008,31:30-35.
6Del Prato S,Felton AM,Munro N,et al.Improving glucosemanagement:ten steps to get more patients with type 2 diabetes toglycaemic goal[J].Int J Clin Pract,2005,59( 11 ):1345-1355.
7中华医学会糖尿病学分会.《中国2010版2型糖尿病防治指南》[D].北京:2010.
8U.K.prospective diabetes study 16.Overview of 6 years' therapy oftype II diabetes:a progressive disease.U.K.Prospective DiabetesStudy Group[J].Diabetes,1995,44(11):1249-1258.
9Mu J,Petrov A,Eiermann GJ,et al.Inhibition of DPP-4 withsitagliptin improves glycemic control and restores islet cell massand function in a rodent model of type 2 diabetes[J].Eur JPharmacol,2009,623(1-3):148-154.
10Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized,parallel, treat-to-target trim comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes [J]. Diabetes Care, 2006,29 (6) : 1269-1274.
